par Delbart, Wendy ;Karabet, Jirair;Marin, Gwennaëlle ;Penninckx, Sébastien ;Derrien, Jonathan ;Ghanem, Ghanem Elias ;Flamen, Patrick ;Wimana, Zéna
Référence International journal of molecular sciences, 23, 20
Publication Publié, 2022-10-15
Référence International journal of molecular sciences, 23, 20
Publication Publié, 2022-10-15
Article révisé par les pairs
Résumé : | Radionuclide Therapy (RNT) with 177Lu-DOTATATE targeting somatostatin receptors (SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical practice, mainly leading to stable disease. Radiobiology holds promise for RNT improvement but is often extrapolated from external beam radiation therapy (EBRT) studies despite differences in these two radiation-based treatment modalities. In a panel of six human cancer cell lines expressing SSTRs, common radiobiological endpoints (i.e., cell survival, cell cycle, cell death, oxidative stress and DNA damage) were evaluated over time in 177Lu-DOTATATE- and EBRT-treated cells, as well as the radiosensitizing potential of poly (ADP-ribose) polymerase inhibition (PARPi). Our study showed that common radiobiological mechanisms were induced by both 177Lu-DOTATATE and EBRT, but to a different extent and/or with variable kinetics, including in the DNA damage response. A higher radiosensitizing potential of PARPi was observed for EBRT compared to 177Lu-DOTATATE. Our data reinforce the need for dedicated RNT radiobiology studies, in order to derive its maximum therapeutic benefit. |